Alzheimer Mechanisms and Therapeutic Strategies
暂无分享,去创建一个
[1] M. Franceschi,et al. Decreased CSF concentrations of homovanillic acid and gamma-aminobutyric acid in Alzheimer's disease. Age- or disease-related modifications? , 1982, Archives of Neurology.
[2] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[3] D. Holtzman,et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[4] A. Roses,et al. Neurodegeneration in the Central Nervous System of apoE-Deficient Mice , 1995, Experimental Neurology.
[5] J. Morris,et al. Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.
[6] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[7] A. Delacourte,et al. Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele , 1998, Neuroscience Letters.
[8] L. Mucke,et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[9] M. Farrer,et al. Molecular mapping of alzheimer‐type dementia in Down's syndrome , 1998, Annals of neurology.
[10] B. Dubois,et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. , 1999, American journal of human genetics.
[11] S. Paul,et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[13] W. Jagust,et al. The Role of APOE ∊4 in Modulating Effects of Other Risk Factors for Cognitive Decline in Elderly Persons , 1999 .
[14] A. Fagan,et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. , 1999, The Journal of clinical investigation.
[15] Matthias Orth,et al. Expression of Human Apolipoprotein E3 or E4 in the Brains ofApoe−/− Mice: Isoform-Specific Effects on Neurodegeneration , 1999, The Journal of Neuroscience.
[16] W. Jagust,et al. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. , 1999, JAMA.
[17] A. Fagan,et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[18] J. Mazziotta,et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[19] V. Haroutunian,et al. Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype , 2000, Annals of neurology.
[20] L. Mucke,et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[21] Makoto Hashimoto,et al. β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[22] D. Holtzman,et al. Behavioral Phenotyping of GFAP-ApoE3 and -ApoE4 Transgenic Mice: ApoE4 Mice Show Profound Working Memory Impairments in the Absence of Alzheimer's-like Neuropathology , 2001, Experimental Neurology.
[23] R. Mahley,et al. Apolipoprotein E4 Potentiates Amyloid β Peptide-induced Lysosomal Leakage and Apoptosis in Neuronal Cells* , 2002, The Journal of Biological Chemistry.
[24] L. Mucke,et al. Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation , 2002, The Journal of Neuroscience.
[25] L. Mucke,et al. Androgens Protect against Apolipoprotein E4-Induced Cognitive Deficits , 2002, The Journal of Neuroscience.
[26] Jacob Raber,et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[27] L. Mucke,et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] Robert B Wallace,et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.
[29] J. Morrison,et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.
[30] L. Mucke,et al. Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice , 2004, The Journal of Neuroscience.
[31] S. Paul,et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.
[32] R. Mahley,et al. Astroglial Regulation of Apolipoprotein E Expression in Neuronal Cells , 2004, Journal of Biological Chemistry.
[33] Tony Wyss-Coray,et al. Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.
[34] Lars Bäckman,et al. Apolipoprotein E and cognitive performance: a meta-analysis. , 2004, Psychology and aging.
[35] Chi Li,et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] Takeshi Iwatsubo,et al. Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins* , 2005, Journal of Biological Chemistry.
[37] R. Takahashi,et al. In vivo evidence of CHIP up‐regulation attenuating tau aggregation , 2005, Journal of neurochemistry.
[38] E. Masliah,et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.
[39] R. Mahley,et al. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[41] Makoto Hashimoto,et al. Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.
[42] I. Kuntz,et al. 4 enhances amyloid beta peptide production in cultured neuronal cells : ApoE structure as a potential therapeutic target , 2005 .
[43] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[44] K. Sleegers,et al. Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. , 2006, Brain : a journal of neurology.
[45] Yadong Huang. Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. , 2006, Current opinion in drug discovery & development.
[46] D. Campion,et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.
[47] D. Quartermain,et al. Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease , 2006, Proceedings of the National Academy of Sciences.
[48] R. Mahley,et al. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[49] David Walker,et al. Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus , 2006, The Journal of Neuroscience.
[50] L. Mucke,et al. A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.
[51] L. Mucke,et al. Reelin Depletion in the Entorhinal Cortex of Human Amyloid Precursor Protein Transgenic Mice and Humans with Alzheimer's Disease , 2007, The Journal of Neuroscience.
[52] Cam Patterson,et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. , 2007, The Journal of clinical investigation.
[53] Ayodeji A. Asuni,et al. Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements , 2007, The Journal of Neuroscience.
[54] H. Soininen,et al. Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients , 2007, Journal of Neurology.
[55] Li-Huei Tsai,et al. Recovery of learning and memory is associated with chromatin remodelling , 2007, Nature.
[56] R. Vink,et al. Traumatic brain injury and Alzheimer's disease: a review. , 2007, Progress in brain research.
[57] H. Arai,et al. Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies , 2007, Brain Research.
[58] S. Maeda,et al. Molecular chaperone‐mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain , 2007, Journal of Neuroscience Research.
[59] J. Silverman,et al. Cardiovascular risk factors for Alzheimer's disease. , 2007, The American journal of geriatric cardiology.
[60] J. Trojanowski,et al. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.
[61] Deanna Greenstein,et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study , 2007, The Lancet Neurology.
[62] O. Touloumi,et al. Activity-Dependent Neuroprotective Protein Snippet NAP Reduces Tau Hyperphosphorylation and Enhances Learning in a Novel Transgenic Mouse Model , 2007, Journal of Pharmacology and Experimental Therapeutics.
[63] M. Vitek,et al. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. , 2007, Journal of neurotrauma.
[64] S. Aalto,et al. Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. , 2008, Archives of neurology.
[65] K. Blennow,et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial , 2008, The Lancet Neurology.
[66] L. Mucke,et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease , 2008, Nature Neuroscience.
[67] M. Pangalos,et al. Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels , 2008, The Journal of Neuroscience.
[68] L. Mucke,et al. Paths of Convergence: Sirtuins in Aging and Neurodegeneration , 2008, Neuron.
[69] L. Mucke,et al. Enkephalin Elevations Contribute to Neuronal and Behavioral Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.
[70] Katie Hamm,et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.
[71] Yadong Huang,et al. Intron-3 Retention/Splicing Controls Neuronal Expression of Apolipoprotein E in the CNS , 2008, The Journal of Neuroscience.
[72] Brian Spencer,et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. , 2008, The Journal of clinical investigation.
[73] G. McKhann,et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease , 2008, Nature Medicine.
[74] T. Gura. Hope in Alzheimer's fight emerges from unexpected places , 2008, Nature Network Boston.
[75] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[76] Guojun Bu,et al. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.
[77] Masanori Nakagawa,et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. , 2009, Archives of neurology.
[78] G. Alexander,et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. , 2009, The New England journal of medicine.
[79] M. Vitek,et al. Apolipoprotein E-Mimetics Inhibit Neurodegeneration and Restore Cognitive Functions in a Transgenic Drosophila Model of Alzheimer's Disease , 2009, PloS one.
[80] E. Masliah,et al. Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice , 2010, Cell.
[81] K. Weisgraber,et al. Understanding the Association of Apolipoprotein E4 with Alzheimer Disease: Clues from Its Structure* , 2009, Journal of Biological Chemistry.
[82] Robert C Green,et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.
[83] Yong Shen,et al. Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain , 2009, Proceedings of the National Academy of Sciences.
[84] J. Becker,et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.
[85] E. Sigurdsson. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. , 2009, Current Alzheimer research.
[86] E. Weeber,et al. ApoE4 Decreases Spine Density and Dendritic Complexity in Cortical Neurons In Vivo , 2009, The Journal of Neuroscience.
[87] Bruce H. Morimoto,et al. Addressing Alzheimer's disease tangles: from NAP to AL-108. , 2009, Current Alzheimer research.
[88] D. Berlau,et al. APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old , 2009, Neurology.
[89] D. Holtzman,et al. The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.
[90] J. Trojanowski,et al. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.
[91] Hui Zheng,et al. Amyloid Precursor Protein Regulates Cav1.2 L-type Calcium Channel Levels and Function to Influence GABAergic Short-Term Plasticity , 2009, The Journal of Neuroscience.
[92] L. Mucke,et al. Collagen VI protects neurons against Aβ toxicity , 2009, Nature Neuroscience.
[93] F. Nicoletti,et al. β-Amyloid Monomers Are Neuroprotective , 2009, The Journal of Neuroscience.
[94] L. Mucke,et al. Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.
[95] Joachim Herz,et al. Reelin signaling antagonizes β-amyloid at the synapse , 2009, Proceedings of the National Academy of Sciences.
[96] P. Matthews,et al. Distinct patterns of brain activity in young carriers of the APOE e4 allele , 2009, NeuroImage.
[97] Keith A. Johnson,et al. Functional Alterations in Memory Networks in Early Alzheimer’s Disease , 2010, NeuroMolecular Medicine.
[98] L. Schiapparelli,et al. Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Aβ levels , 2009, Neurobiology of Disease.
[99] F. Liu,et al. Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice , 2009, The Journal of Neuroscience.
[100] A. Fagan,et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.
[101] R. Mahley,et al. GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. , 2009, Cell stem cell.
[102] B. Brew,et al. Neuropsychological Functioning and Antiretroviral Treatment in HIV/AIDS: A Review , 2009, Neuropsychology Review.
[103] J. Herz,et al. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling , 2010, Proceedings of the National Academy of Sciences.
[104] Rie Teraoka,et al. A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.
[105] R. Tanzi,et al. The Genetics of Alzheimer Disease: Back to the Future , 2010, Neuron.
[106] Julie A. Harris,et al. Many Neuronal and Behavioral Impairments in Transgenic Mouse Models of Alzheimer's Disease Are Independent of Caspase Cleavage of the Amyloid Precursor Protein , 2010, The Journal of Neuroscience.
[107] Karl Herrup,et al. Reimagining Alzheimer's Disease—An Age-Based Hypothesis , 2010, The Journal of Neuroscience.
[108] L. Mucke,et al. Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice. , 2010, The American journal of pathology.
[109] Kai Zhang,et al. Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport , 2010, Science.
[110] E. Mandelkow,et al. Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.
[111] W. Klein,et al. Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5 , 2010, Neuron.
[112] Yadong Huang,et al. Apolipoprotein E4 Causes Age- and Tau-Dependent Impairment of GABAergic Interneurons, Leading to Learning and Memory Deficits in Mice , 2010, The Journal of Neuroscience.
[113] Lennart Opitz,et al. Altered Histone Acetylation Is Associated with Age-Dependent Memory Impairment in Mice , 2010, Science.
[114] Donald Silberberg,et al. National Institutes of Health State-of-the-Science Conference Statement: Preventing Alzheimer Disease* and Cognitive Decline , 2010, Annals of Internal Medicine.
[115] G. Cole,et al. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. , 2010, CNS & neurological disorders drug targets.
[116] Mathias Jucker,et al. The benefits and limitations of animal models for translational research in neurodegenerative diseases , 2010, Nature Medicine.
[117] B. Strooper,et al. The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.
[118] I. Bezprozvanny. The rise and fall of Dimebon. , 2010, Drug News and Perspectives.
[119] C. Masters,et al. Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease , 2010, Cell.
[120] K. Zahs,et al. Probing the Biology of Alzheimer's Disease in Mice , 2010, Neuron.
[121] F. LaFerla,et al. Alzheimer's disease. , 2010, The New England journal of medicine.
[122] E. Yaksi,et al. Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy , 2010, Neuron.
[123] K. J. Lee,et al. Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines , 2010, Neuroscience.
[124] J. Trojanowski,et al. Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy , 2010, The Journal of Neuroscience.
[125] Michela Gallagher,et al. Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive Impairment , 2010, Neuropsychopharmacology.
[126] Fei Liu,et al. Tau in Alzheimer disease and related tauopathies. , 2010, Current Alzheimer research.
[127] Nick C Fox,et al. The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.
[128] J. Kuret,et al. Imaging as a strategy for premortem diagnosis and staging of tauopathies. , 2010, Current Alzheimer Research.
[129] S. Ferreira,et al. Amyloid-β Peptide Oligomers Disrupt Axonal Transport through an NMDA Receptor-Dependent Mechanism That Is Mediated by Glycogen Synthase Kinase 3β in Primary Cultured Hippocampal Neurons , 2010, The Journal of Neuroscience.
[130] V. Perry,et al. Microglia in neurodegenerative disease , 2010, Nature Reviews Neurology.
[131] Wendy R. Sanhai,et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.
[132] S. Horvath,et al. Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways , 2010, Proceedings of the National Academy of Sciences.
[133] Brad J Kolls,et al. A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.
[134] M. Citron,et al. Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.
[135] Jared Stokes,et al. Temporal lobe functional activity and connectivity in young adult APOE ɛ4 carriers , 2010, Alzheimer's & Dementia.
[136] K. Zahs,et al. ‘Too much good news’ – are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? , 2010, Trends in Neurosciences.
[137] K. Ashe,et al. Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.
[138] Hyoung-Gon Lee,et al. Antioxidant approaches for the treatment of Alzheimer’s disease , 2010, Expert review of neurotherapeutics.
[139] L. Mucke,et al. Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.
[140] Yadong Huang,et al. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. , 2010, Trends in molecular medicine.
[141] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[142] H. Steinbusch,et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease , 2010, Progress in Neurobiology.
[143] G. Collingridge,et al. Aβ1–42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β , 2011, Nature Neuroscience.
[144] R. Huganir,et al. Arc/Arg3.1 Regulates an Endosomal Pathway Essential for Activity-Dependent β-Amyloid Generation , 2011, Cell.
[145] S. Rapcsak,et al. Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes , 2011, Neurology.
[146] Todd E. Golde,et al. Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.
[147] David M Holtzman,et al. Human Apoe Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance Nih Public Access , 2022 .
[148] K. Reymann,et al. Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors , 2011, Neurobiology of Aging.
[149] N. Schor. What the halted phase III γ‐secretase inhibitor trial may (or may not) be telling us , 2011, Annals of Neurology.
[150] Dietmar R. Thal,et al. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.
[151] Yong Ji,et al. Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. , 2011, Journal of Alzheimer's Disease.
[152] M. Gatz,et al. Relationship Between Education and Dementia: An Updated Systematic Review , 2011, Alzheimer disease and associated disorders.
[153] Meaghan Morris,et al. The Many Faces of Tau , 2011, Neuron.
[154] Jürgen Götz,et al. Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.
[155] A. Palmeri,et al. Endogenous amyloid‐β is necessary for hippocampal synaptic plasticity and memory , 2011, Annals of neurology.
[156] D. Holtzman,et al. Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis , 2011, The Journal of Neuroscience.
[157] Daniela Galimberti,et al. Inflammation and oxidative damage in Alzheimer's disease: friend or foe? , 2011, Frontiers in Bioscience.
[158] J. David Sweatt,et al. Epigenetic Mechanisms in Cognition , 2011, Neuron.
[159] M. Mattson,et al. Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. , 2011, Biochimica et biophysica acta.
[160] Kewei Chen,et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.
[161] K. Yaffe,et al. The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.
[162] Julie Harris,et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model , 2011, Nature.
[163] H. Marie,et al. Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models? , 2011, Alzheimer's & Dementia.
[164] R. Mahley,et al. Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons* , 2011, The Journal of Biological Chemistry.
[165] Jee Hoon Roh,et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.
[166] Kimberly Scearce-Levie,et al. Animal Models of Alzheimer's Disease: Modeling Targets, Not Disease Accelerating Drug Discovery for Alzheimer's Disease: Best Practices for Preclinical Animal Studies , 2022 .
[167] B. Strooper,et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.
[168] D. German,et al. Identification of Candidate IgG Biomarkers for Alzheimer's Disease via Combinatorial Library Screening , 2011, Cell.
[169] Clifford R. Jack,et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.
[170] Shaomin Li,et al. Soluble Aβ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors , 2011, The Journal of Neuroscience.
[171] Yadong Huang,et al. C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-β (Aβ) and acts in concert with Aβ to elicit neuronal and behavioral deficits in mice , 2011, Proceedings of the National Academy of Sciences.
[172] Chengjie Xiong,et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.
[173] R. Schirmer,et al. “Lest we forget you — methylene blue …” , 2011, Neurobiology of Aging.
[174] Phillip B. Jones,et al. Apolipoprotein E: Isoform Specific Differences in Tertiary Structure and Interaction with Amyloid-β in Human Alzheimer Brain , 2011, PloS one.
[175] V. Srikanth,et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease , 2011, Neurobiology of Aging.
[176] M. Jucker,et al. Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders , 2011, Annals of neurology.
[177] Hélène Marie,et al. Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models? , 2011, Alzheimer's & Dementia.
[178] Scott A. Peterson,et al. Structure-dependent Impairment of Intracellular Apolipoprotein E4 Trafficking and Its Detrimental Effects Are Rescued by Small-molecule Structure Correctors* , 2011, The Journal of Biological Chemistry.
[179] J. Trojanowski,et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. , 2011, Nature communications.
[180] M. Vogt,et al. APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP , 2011, The EMBO journal.
[181] J. Kaye,et al. The aging systemic milieu negatively regulates neurogenesis and cognitive function , 2011, Nature.
[182] Identification of dihydropyridines that reduce cellular tau levels. , 2011, Chemical Communications.
[183] H. Braak,et al. Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? , 2011, Acta Neuropathologica.
[184] Fred H. Gage,et al. In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.
[185] P. Bosco,et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance , 2011, Molecular Psychiatry.
[186] Jurg Ott,et al. Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study , 2011, Neurobiology of Aging.
[187] Kelly O'Keefe,et al. Hippocampal Hyperactivation Associated with Cortical Thinning in Alzheimer's Disease Signature Regions in Non-Demented Elderly Adults , 2011, The Journal of Neuroscience.
[188] P. Tariot,et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease , 2011, Neurology.
[189] M. Ohno,et al. Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis , 2011, Autophagy.
[190] Fred H. Gage,et al. Modelling schizophrenia using human induced pluripotent stem cells , 2011, Nature.
[191] Ezzie Hutchinson,et al. Systems neuroscience: The stress of dieting , 2011, Nature Reviews Neuroscience.
[192] M. Albert,et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[193] H. Mori,et al. Clinical Course of Patients with Familial Early-Onset Alzheimer’s Disease Potentially Lacking Senile Plaques Bearing the E693Δ Mutation in Amyloid Precursor Protein , 2011, Dementia and Geriatric Cognitive Disorders.
[194] B. Shaby,et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration , 2011, Nature chemical biology.
[195] D. Brooks,et al. Inflammatory risk factors and pathologies associated with Alzheimer's disease. , 2011, Current Alzheimer Research.
[196] L. Hood,et al. Systems medicine and integrated care to combat chronic noncommunicable diseases , 2011, Genome Medicine.
[197] Ralph A. Nixon,et al. Autophagy failure in Alzheimer's disease—locating the primary defect , 2011, Neurobiology of Disease.
[198] Robert C Green,et al. A comprehensive genetic association study of Alzheimer disease in African Americans. , 2011, Archives of neurology.
[199] A. Gillespie,et al. Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent Aβ Accumulation in Mutant Human Amyloid Precursor Protein Transgenic Mice , 2012, The Journal of Neuroscience.
[200] Qian Cai,et al. Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration , 2012, Nature Reviews Neuroscience.
[201] B. Strooper,et al. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.
[202] Kristopher L. Nazor,et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells , 2012, Nature.
[203] Jason J. Corneveaux,et al. A genome-wide scan for common variants affecting the rate of age-related cognitive decline , 2012, Neurobiology of Aging.
[204] Edward O. Mann,et al. Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model , 2012, Cell.
[205] D. Rubinsztein,et al. Control of autophagy as a therapy for neurodegenerative disease , 2012, Nature Reviews Neurology.
[206] A. Salehi,et al. Neurobiological Elements of Cognitive Dysfunction in Down Syndrome: Exploring the Role of APP , 2012, Biological Psychiatry.
[207] K. Vossel,et al. ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease , 2013, Neurocase.